XDx Selects Ingenuity Systems IPA 5.0 for Pathways Solution

New IPA-Biomarker™ Capability Critical for Expression Diagnostics Discovery and Development

Redwood City, CA – July 10, 2007 – Ingenuity Systems, the leading provider of solutions to explore, analyze, and interpret scientific literature and data, today announced that XDx, a leading molecular diagnostics company, has licensed Ingenuity’s flagship solution IPA 5.0. Ingenuity Systems was selected by XDx after a comprehensive evaluation of several pathway analysis products.

Founded in 2000, XDx is a molecular diagnostics company based in Brisbane, California. Setting the stage for a new era in personalized medicine, XDx is one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project. The company has developed a proprietary new method for noninvasively monitoring the immune system by measuring gene expression in a patient’s peripheral blood. The technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

“We chose IPA because it best meets our objective to identify and understand biomarkers associated with immune-mediated diseases,” commented Dr. Tod Klingler, VP of Informatics at XDx. “IPA provides us with access to its extensive knowledge base of gene function information assembled from the scientific literature through easy-to-use tools that our researchers can use to rapidly evaluate candidate biomarkers. Specifically, IPA allows us to make sense of our gene expression data in the context of known immune system interactions and pathways.”

“We are very pleased to have been selected by XDx as an important tool in their research programs,” stated Peter DiLaura, Senior Vice President, Commercial Operations at Ingenuity Systems. “As with many of our customers involved in biomarker research, IPA is well-suited for XDx because the expansive, expert-extracted scientific content can be applied in their initial exploratory research, and then tools in IPA, such as IPA-Biomarker™, can be used to identify or compare their biomarker candidates. IPA 5.0 enables them to apply filters to their data to determine whether a particular gene or protein is detectable in sentinel tissues or other bodily fluids, so potential candidates are identified much more effectively than in traditional approaches.”

IPA is a software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA is deployed in all major pharmaceutical companies and in hundreds of biotechnology companies and academic institutions globally. It supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, identification of biomarkers, predictive toxicology, and pharmacogenomics.

Trials of IPA 5.0 are currently being offered at http://www.ingenuity.com/trial/start.html. For more information about IPA, please email sales@ingenuity.com or go to www.ingenuity.com

About Ingenuity Systems®

Ingenuity enables researchers to model, analyze, and understand complex biological and chemical systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for life scientists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.

About XDx

XDx’s mission is to improve patient care by developing molecular diagnostics that translate an individual’s immune status into clinically actionable information.

XDx is a molecular diagnostics company that utilizes state-of-the-art genomic technology and sophisticated bioinformatics analyses to understand and measure the immune processes that underlie specific immune-mediated conditions. Physicians can use this information to optimize patient treatment and minimize the long-term consequences of immunosuppressive therapies.

XDx’s science and technology is now being evaluated in patients with solid organ transplants. Building on the discoveries made during the development of AlloMap® testing for heart transplant patients, which included the identification of many genes and pathways involved in tissue rejection, XDx is now developing a product for use by physicians to better manage lung transplant patients.

Beyond the use of AlloMap testing in assessing immune response in solid organ transplantation, XDx scientists are applying similar approaches to create new molecular diagnostic tests for the improved clinical management of immune-mediated inflammatory diseases, such as systemic lupus erythematosus (SLE or lupus,) to diagnose and predict clinical flares common in a variety of these diseases.